Sarepta Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Sarepta Therapeutics
SRPT Stock  USD 20.72  0.38  1.87%   
Analyzing historical trends in various income statement and balance sheet accounts from Sarepta Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Sarepta Therapeutics' valuation are summarized below:
Gross Profit
443.8 M
Profit Margin
(0.11)
Market Capitalization
2.2 B
Enterprise Value Revenue
1.0484
Revenue
2.4 B
There are currently one hundred twenty fundamental trend indicators for Sarepta Therapeutics that can be evaluated and compared over time across competition. All traders should double-check Sarepta Therapeutics' current fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 10.7 B in 2026. Enterprise Value is likely to gain to about 11.3 B in 2026

Sarepta Therapeutics Total Revenue

2.3 Billion

Check Sarepta Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sarepta Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 45.6 M, Interest Expense of 10.7 M or Selling General Administrative of 673.6 M, as well as many indicators such as Price To Sales Ratio of 6.64, Dividend Yield of 0.0 or PTB Ratio of 6.75. Sarepta financial statements analysis is a perfect complement when working with Sarepta Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Sarepta Stock
Check out the analysis of Sarepta Therapeutics Correlation against competitors.
For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.

Sarepta Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets4.8 B4.6 B1.9 B
Slightly volatile
Other Current Liabilities430 M409.5 M139.6 M
Slightly volatile
Total Current Liabilities883.5 M841.4 M319.8 M
Slightly volatile
Total Stockholder Equity1.8 B1.8 B698.9 M
Slightly volatile
Property Plant And Equipment Net590 M561.9 M188.6 M
Slightly volatile
Accounts Payable258.9 M246.6 M80.9 M
Slightly volatile
Cash1.3 B1.3 B663.8 M
Slightly volatile
Non Current Assets Total1.1 B1 B360.3 M
Slightly volatile
Non Currrent Assets Other286.5 M272.9 M106.4 M
Slightly volatile
Cash And Short Term Investments1.6 B1.6 B991.3 M
Slightly volatile
Common Stock Total Equity7.7 K8.1 K189.1 K
Slightly volatile
Common Stock Shares Outstanding130.3 M124.1 M65.4 M
Slightly volatile
Liabilities And Stockholders Equity4.8 B4.6 B1.9 B
Slightly volatile
Other Stockholder Equity6.9 B6.6 B2.9 B
Slightly volatile
Total Liabilities2.9 B2.8 B1.2 B
Slightly volatile
Property Plant And Equipment Gross872.8 M831.2 M261.5 M
Slightly volatile
Total Current Assets3.7 B3.5 B1.5 B
Slightly volatile
Intangible Assets32.5 M30.9 M13.5 M
Slightly volatile
Common Stock8.6 K9 K189.3 K
Slightly volatile
Non Current Liabilities Total2.1 B2 B872.7 M
Slightly volatile
Other Current Assets385.2 M366.8 M96.2 M
Slightly volatile
Other Assets1.091.1565.9 M
Slightly volatile
Property Plant Equipment295.8 M281.7 M123.6 M
Slightly volatile
Net Receivables784.5 M747.2 M199.3 M
Slightly volatile
Short and Long Term Debt Total1.6 B1.5 B697.3 M
Slightly volatile
Other Liabilities630.2 M600.2 M248.1 M
Slightly volatile
Current Deferred Revenue157.3 M149.8 M46.2 M
Slightly volatile
Long Term Debt1.4 B1.3 B596.7 M
Slightly volatile
Net Tangible Assets530.3 M434 M443.1 M
Slightly volatile
Long Term Debt Total1.3 B1.3 B560.9 M
Slightly volatile
Capital Surpluse5 B4.8 B2.5 B
Slightly volatile
Non Current Liabilities Other53.7 M56.5 M108.6 M
Pretty Stable
Short and Long Term Debt127.4 M121.3 M60.3 M
Slightly volatile
Net Invested Capital2 B3.1 B1.7 B
Slightly volatile
Long Term Investments165.3 M157.4 M52 M
Slightly volatile
Net Working Capital1.9 B2.7 B1.6 B
Slightly volatile
Capital Stock9.4 K11.5 K8.1 K
Slightly volatile
Capital Lease Obligations248.7 M236.8 M88.6 M
Slightly volatile

Sarepta Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization45.6 M43.4 M20.9 M
Slightly volatile
Selling General Administrative673.6 M641.6 M252.4 M
Slightly volatile
Total Revenue2.3 B2.2 B632.7 M
Slightly volatile
Other Operating Expenses2 B1.9 B813.1 M
Slightly volatile
Research Development971.5 M925.2 M453 M
Slightly volatile
Total Operating Expenses1.6 B1.6 B717.8 M
Slightly volatile
Interest Income86.7 M82.5 M20.3 M
Slightly volatile
Non Recurring209.2 M199.2 M108.7 M
Slightly volatile
Selling And Marketing Expenses34.5 M32.9 M10.9 M
Slightly volatile
Reconciled Depreciation32.9 M43.4 M21.9 M
Slightly volatile

Sarepta Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation45.6 M43.4 M20.1 M
Slightly volatile
Capital Expenditures177.4 M169 M54.4 M
Slightly volatile
Total Cash From Financing Activities184.4 M143.5 M300.1 M
Pretty Stable
Begin Period Cash Flow300.8 M510.6 M499.3 M
Slightly volatile
Stock Based Compensation222.5 M211.9 M89.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.646.99139
Slightly volatile
PTB Ratio6.758.79.3505
Pretty Stable
Days Sales Outstanding122112168
Pretty Stable
Book Value Per Share15.1914.469.0574
Slightly volatile
Average Payables3 M3.4 M3.7 M
Slightly volatile
Stock Based Compensation To Revenue0.08280.08722.1142
Pretty Stable
Capex To Depreciation1.833.512.458
Very volatile
PB Ratio6.758.79.3505
Pretty Stable
EV To Sales6.787.13132
Slightly volatile
Sales General And Administrative To Revenue0.320.345.2745
Pretty Stable
Research And Ddevelopement To Revenue0.460.4912.354
Slightly volatile
Capex To Revenue0.08440.08890.7052
Slightly volatile
Cash Per Share7.0712.8212.4548
Slightly volatile
Intangibles To Total Assets0.00740.00780.0255
Slightly volatile
Current Ratio8.674.837.531
Slightly volatile
Tangible Book Value Per Share14.9214.218.8498
Slightly volatile
Receivables Turnover5.213.374.4388
Slightly volatile
Graham Number23.9326.9229.3816
Slightly volatile
Shareholders Equity Per Share15.1914.469.0623
Slightly volatile
Debt To Equity0.50.790.7581
Slightly volatile
Capex Per Share1.461.390.6351
Slightly volatile
Average Receivables4.1 M4.1 M3.6 M
Slightly volatile
Revenue Per Share18.918.06.6808
Slightly volatile
Interest Debt Per Share13.5312.897.7203
Slightly volatile
Debt To Assets0.320.30.228
Slightly volatile
Price Book Value Ratio6.758.79.3505
Pretty Stable
Ebt Per Ebit1.291.381.2147
Very volatile
Company Equity Multiplier2.452.332.4506
Slightly volatile
Long Term Debt To Capitalization0.40.380.2958
Slightly volatile
Total Debt To Capitalization0.440.420.3145
Slightly volatile
Debt Equity Ratio0.50.790.7581
Slightly volatile
Quick Ratio3.473.656.7635
Slightly volatile
Net Income Per E B T1.31.041.0376
Pretty Stable
Cash Ratio1.651.732.7158
Pretty Stable
Days Of Sales Outstanding122112168
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.221.971.1472
Slightly volatile
Price To Book Ratio6.758.79.3505
Pretty Stable
Fixed Asset Turnover1.943.53.1737
Pretty Stable
Debt Ratio0.320.30.228
Slightly volatile
Price Sales Ratio6.646.99139
Slightly volatile
Asset Turnover0.450.430.2437
Slightly volatile
Price Fair Value6.758.79.3505
Pretty Stable

Sarepta Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap10.7 B10.2 B6.9 B
Slightly volatile
Enterprise Value11.3 B10.8 B7.2 B
Slightly volatile

Sarepta Fundamental Market Drivers

Forward Price Earnings16.3934
Cash And Short Term Investments1.4 B

Sarepta Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Sarepta Therapeutics Financial Statements

Sarepta Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Sarepta Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Sarepta Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Sarepta Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue149.8 M157.3 M
Total Revenue2.2 B2.3 B
Cost Of Revenue367 M385.3 M
Stock Based Compensation To Revenue 0.09  0.08 
Sales General And Administrative To Revenue 0.34  0.32 
Research And Ddevelopement To Revenue 0.49  0.46 
Capex To Revenue 0.09  0.08 
Revenue Per Share 18.00  18.90 
Ebit Per Revenue 0.10  0.11 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Sarepta Stock Analysis

When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY